Srinagar Magazine

Autosomal Dominant Polycystic Kidney Disease Epidemiology Forecast, Diagnosis, Treatment Options | DelveInsight

 Breaking News
  • No posts were found

Autosomal Dominant Polycystic Kidney Disease Epidemiology Forecast, Diagnosis, Treatment Options | DelveInsight

April 02
14:50 2020
Autosomal Dominant Polycystic Kidney Disease Epidemiology Forecast, Diagnosis, Treatment Options | DelveInsight

“Autosomal Dominant Polycystic Kidney Disease – Epidemiology Forecast to 2030”

 

DelveInsight has launched a new report on Autosomal Dominant Polycystic Kidney Disease – Epidemiology Forecast to 2030

DelveInsight’s ‘Autosomal Dominant Polycystic Kidney Disease – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Autosomal Dominant Polycystic Kidney Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Some of the key facts of the Report:

  1. The prevalence of ADPKD is estimated to range from 1 in 400 to 1000 live births, with 5,000–6,000 new cases diagnosed each year.
  2. The majority prevalent cases of ADPKD were recorded in the United States.
  3. The lowest prevalent population of ADPKD was recorded in Japan.
  4. The prevalence of ADPKD increased with age and reached a peak value of 261 per million population at the age group of 55-59 years.

 

 “According to DelveInsight’s analysis, ADPKD is the most common in adults and is most frequent in higher age groups and 50% of ADPKD may progress to ESRD by 60 years of age.”

 

 

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a genetic disorder which causes pathological cystic changes to the kidney and is characterized by numerous renal and systemic manifestations. Renal manifestations are produced by the progressive and continuous enlargement and proliferation of fluid-filled cysts, leading to enlargement of the kidney up to five times the normal volume in the years prior to the development of kidney failure.

ADPKD may led to development of end-stage renal disease (ESRD) and is the fourth most common renal disease requiring renal replacement therapy (RRP). The most common extrarenal manifestation is polycystic liver disease (PLD), which is more common in women than in men.

Genetic mutation plays a major role in the pathogenesis of ADPKD, mainly mutations in the PKD1, PKD2 genes leads to cyst formation and its progressive growth.

As per the WHO classification, there are two types of PKD: autosomal dominant (ADPKD) and autosomal recessive (ARPKD). The gene mutations in the PKHD1 gene cause ARPKD, occurring mostly in children.

 

“According to DelveInsight, DelveInsight’s Analysis, it can be observed that diagnosis of ADPKD is high in the 7MM.”

 

Request for Sample Pages https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-epidemiology-forecast

 

Scope of the Report

  • The Autosomal Dominant Polycystic Kidney Disease report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Autosomal Dominant Polycystic Kidney Disease Epidemiology Report and Model provide an overview of the risk factors and global trends of Autosomal Dominant Polycystic Kidney Disease in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Autosomal Dominant Polycystic Kidney Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Autosomal Dominant Polycystic Kidney Disease
  • The report provides the segmentation of the Autosomal Dominant Polycystic Kidney Disease epidemiology

 

KOL- Views

We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

 

Request for Sample Pages https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-epidemiology-forecast

 

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Autosomal Dominant Polycystic Kidney Disease?
  • What are the key findings pertaining to the Autosomal Dominant Polycystic Kidney Disease epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Autosomal Dominant Polycystic Kidney Disease across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Autosomal Dominant Polycystic Kidney Disease?
  • What are the currently available treatments of Autosomal Dominant Polycystic Kidney Disease?

 

Reasons to buy

  • The Autosomal Dominant Polycystic Kidney Disease Epidemiology report will allow the user to –
  • Develop business strategies by understanding the trends shaping and driving the global Autosomal Dominant Polycystic Kidney Disease market
  • Quantify patient populations in the global Autosomal Dominant Polycystic Kidney Disease market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Autosomal Dominant Polycystic Kidney Disease therapeutics in each of the markets covered
  • Understand the magnitude of Autosomal Dominant Polycystic Kidney Disease population by its epidemiology
  • The Autosomal Dominant Polycystic Kidney Disease Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

 

Related Reports:

Autosomal Dominant Polycystic Kidney Disease – Pipeline Insights, 2020

The Autosomal Dominant Polycystic Kidney Disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Autosomal Dominant Polycystic Kidney Disease across the complete product development cycle, including all clinical and nonclinical stages.

Autosomal Dominant Polycystic Kidney Disease- Market Insight, Epidemiology and Market Forecast -2030

The Autosomal Dominant Polycystic Kidney Disease market report provides current treatment practices, emerging drugs, Autosomal Dominant Polycystic Kidney Disease market share of the individual therapies, current and forecasted Autosomal Dominant Polycystic Kidney Disease market Size from 2017 to 2030 segmented by seven major markets.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NEVADA 89107
Country: United States
Website: https://www.delveinsight.com/

Related Articles